4-苯基哌啶-4-甲醇 | 4220-08-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-苯基哌啶-4-甲醇
• 中文别名: (4-苯基哌啶-4-基)甲醇
• 英文名称: (4-phenyl-piperidin-4-yl)-methanol
• 英文别名: 4-phenylpiperidine-4-methanol；(4-phenyl-piperidine-4-yl)-methanol；4-hydroxymethyl-4-phenyl-piperidine；4-Hydroxymethyl-4-phenylpiperidine；(4-phenyl-piperidin-4-yl)methanol；(4-phenylpiperidin-4-yl)methanol
• CAS: 4220-08-0
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: YXDQCHJILIFZBY-UHFFFAOYSA-N

物化性质

• 熔点：
  171 °C(Solv: acetone (67-64-1))
• 沸点：
  323.0±35.0 °C(Predicted)
• 密度：
  1.041±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-苯基哌啶-4-甲醇 在 Rh/Al₂O₃ 盐酸 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Design and Pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a Potent, Selective, Melanocortin Subtype-4 Receptor Agonist

  摘要：

  Synthetic and natural peptides that act as nonselective melanocortin receptor agonists have been found to be anorexigenic and to stimulate erectile activity. We report the design and development-of 1, a potent, selective (1184-fold vs MC3R, 350-fold vs MC5R), small-molecule agonist of the MC4 receptor. Pharmacological testing confirms the food intake lowering effects of MC4R agonism and suggests another role for the receptor in the stimulation of erectile activity.

  DOI：

  10.1021/jm025539h
• 作为产物：
  描述：

  去甲哌替啶 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 4-苯基哌啶-4-甲醇
  参考文献：
  名称：

  Design and Pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a Potent, Selective, Melanocortin Subtype-4 Receptor Agonist

  摘要：

  Synthetic and natural peptides that act as nonselective melanocortin receptor agonists have been found to be anorexigenic and to stimulate erectile activity. We report the design and development-of 1, a potent, selective (1184-fold vs MC3R, 350-fold vs MC5R), small-molecule agonist of the MC4 receptor. Pharmacological testing confirms the food intake lowering effects of MC4R agonism and suggests another role for the receptor in the stimulation of erectile activity.

  DOI：

  10.1021/jm025539h

文献信息

• Piperidine derivatives and methods of use
  申请人：Zhang Penglie

  公开号：US20070088036A1

  公开（公告）日：2007-04-19

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并具有体内抗炎活性。这些化合物通常是单环和双环化合物，可用于制药组合物、治疗CCR1介导疾病的方法，以及作为竞争性CCR1拮抗剂鉴定的控制物。
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：Cianchetta Giovanni

  公开号：US20140288081A1

  公开（公告）日：2014-09-25

  Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

  通式I的化合物： 以及包含调节丙酮酸激酶的通式I化合物的组合物在此处被描述。此外，在此处还描述了利用调节丙酮酸激酶的化合物治疗疾病的方法。
• Benzothiazole derivatives with activity as adenosine receptor ligands
  申请人：——

  公开号：US20020045615A1

  公开（公告）日：2002-04-18

  The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.

  本发明涉及替代苯并噻唑衍生物及其药用可接受的盐，用于治疗与腺苷受体相关的疾病。
• NK-1 AND SEROTONIN TRANSPORTER INHIBITORS
  申请人：Degnan P. Andrew

  公开号：US20070249607A1

  公开（公告）日：2007-10-25

  The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

  这项发明涵盖了公式I的化合物，包括药用盐，它们的药物组合物，以及它们在治疗与过多或不平衡的速激肽或血清素或两者都有关的疾病中的用途。
• Substituted Heterocyclic Ethers and Their Use in CNS Disorders
  申请人：Degnan Andrew P.

  公开号：US20090018132A1

  公开（公告）日：2009-01-15

  The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

  这项发明涵盖了公式I的化合物，包括药用盐、它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。